NASDAQ:DERM - Dermira Stock Price, Forecast & News

Dermira trades on the NASDAQ under the ticker symbol "DERM."

Dermira Inc (NASDAQ:DERM) announced its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.40) by $0.34. The biopharmaceutical company had revenue of $11.53 million for the quarter, compared to analysts' expectations of $11.07 million. Dermira had a negative return on equity of 583.07% and a negative net margin of 256.08%. View Dermira's Earnings History.

Dermira is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Dermira.

9 equities research analysts have issued 1-year target prices for Dermira's stock. Their forecasts range from $14.00 to $25.00. On average, they expect Dermira's stock price to reach $18.79 in the next twelve months. This suggests a possible upside of 0.2% from the stock's current price. View Analyst Price Targets for Dermira.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dermira in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dermira.

News stories about DERM stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dermira earned a news impact score of -3.0 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Dermira.

Dermira saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 5,610,000 shares, a drop of 17.5% from the January 15th total of 6,800,000 shares. Based on an average daily trading volume, of 2,400,000 shares, the short-interest ratio is currently 2.3 days. Currently, 12.4% of the shares of the stock are short sold. View Dermira's Current Options Chain.

Some companies that are related to Dermira include FibroGen (FGEN), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), Blueprint Medicines (BPMC), Zai Lab (ZLAB), SAGE Therapeutics (SAGE), Agios Pharmaceuticals (AGIO), PTC Therapeutics (PTCT), Ultragenyx Pharmaceutical (RARE), HUTCHISON CHINA/S (HCM), Emergent Biosolutions (EBS), Genmab A/S (GMAB), Alkermes (ALKS) and Allakos (ALLK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dermira investors own include Gilead Sciences (GILD), Micron Technology (MU), Advanced Micro Devices (AMD), AT&T (T), Exelixis (EXEL), Novavax (NVAX), TG Therapeutics (TGTX), AbbVie (ABBV), Bristol-Myers Squibb (BMY) and ImmunoGen (IMGN).

Dermira's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Fred Alger Management LLC (5.60%), Oracle Investment Management Inc. (4.64%), Bank of America Corp DE (3.70%), State Street Corp (1.80%), Broadfin Capital LLC (1.64%) and Earnest Partners LLC (1.48%). Company insiders that own Dermira stock include David E Cohen, Eagle Acquisition Corp Bald, Eugene A Bauer, Matthew K Fust and Thomas G Wiggans. View Institutional Ownership Trends for Dermira.

DERM stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Credit Suisse AG, Citigroup Inc., Fred Alger Management LLC, Renaissance Technologies LLC, Sofinnova Investments Inc., Panagora Asset Management Inc. and Partner Investment Management L.P.. Company insiders that have sold Dermira company stock in the last year include Eugene A Bauer and Matthew K Fust. View Insider Buying and Selling for Dermira.

DERM stock was bought by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., Jacobs Levy Equity Management Inc., Broadfin Capital LLC, Rhenman & Partners Asset Management AB, Candriam Luxembourg S.C.A., Earnest Partners LLC, Alliancebernstein L.P. and EAM Global Investors LLC. Company insiders that have bought Dermira stock in the last two years include Eagle Acquisition Corp Bald and Thomas G Wiggans. View Insider Buying and Selling for Dermira.

Shares of DERM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DERM stock can currently be purchased for approximately $18.75.

Dermira has a market capitalization of $1.02 billion and generates $42.34 million in revenue each year. The biopharmaceutical company earns $-221,540,000.00 in net income (profit) each year or ($5.24) on an earnings per share basis. Dermira employs 333 workers across the globe.View Additional Information About Dermira.

The official website for Dermira is http://www.dermira.com/.

Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at [email protected]